ALL SOLID TUMORS

OmniSeq INSIGHT℠

Make confident treatment decisions
based on the entire tumor profile

Dynacare®

Genetics and Specialty Services

OmniSeq INSIGHT℠

A single, comprehensive report that provides treatment options for your patient.

The patient report delivers complete INSIGHT into the tumor and its microenvironment by summarizing FDA-approved therapies, immunotherapies and eligible clinical trials for your patient's solid tumor.

From a single tumor biopsy, analyzed by advanced NGS technology, OmniSeq INSIGHT identifies treatment options in one comprehensive, easy-to-read report.

FFPE tissue

- Resection specimens
- Needle core biopsies
- Cell blocks from FNA

- Multiplex DNA and RNA NGS platform
- Protein expression (PD-L1)

Identify approved drug candidates

Comprehensive genomics

- Identifies genomic alterations in 523 genes
- Fusions/splice variants using in RNA-Seq hybrid capture
- Coverage of NCCN® guideline-recommended biomarkers across solid tumor types

Immunotherapy eligibility

Comprehensive immune profiling

- PD-L1 immunohistochemistry (IHC)
- MSI & TMB profiling*
- Immune biomarker drug targets

Eligible clinical trials

List of patient-eligible clinical trials within 200 miles of patient's physical address[1]

- Testing for biomarkers with clinical trial associations

The result report includes:

- A summary page of marker findings
- A therapy considerations section with treatment setting, approval status and multi-marker associations
- Flagged potential cancer-associated hereditary variants

OmniSeq INSIGHT was developed by OmniSeq® and is performed by OmniSeq as a send-out for Dynacare, its Canadian distributor.

A consolidated assay for two different treatment paradigms:

Genomic profiling

- 523 gene NGS panel
- MSI and TMB*
- DNA and RNA sequencing
- SNVs, indels, CNAs and fusions*
- Interrogation of full coding regions

Immune profiling

- PD-L1 immunohistochemistry (IHC)
- 64 RNA expression/immune profiling genes by immune cycle step:
  - T-cell priming/trafficking
  - T-cell recognition
  - T-cell infiltration
  - Killing cancer cells
  - Cancer testis antigens

Why choose OmniSeq INSIGHT?

INSIGHT is the only comprehensive test to contain all of the following:

- Genes aligned with FDA approvals, professional practice guidelines and clinical trials
- HRR/HRD-related* genes for PARP therapeutic selection
- Full coding region coverage for each gene which improves variant detection compared to "hotspot" testing strategies
- An RNA-seq hybrid capture approach which allows for the detection of common and novel fusions
- Targeting of unique emerging and actionable markers
- Immune gene expression (mRNA) analysis to evaluate the interaction between the tumor and its microenvironment

When to consider OmniSeq INSIGHT:

INSIGHT may be useful as a tool in various clinical settings, including:

- When guidelines recommend broad genomic profiling to evaluate genes with clinical evidence and therapeutic recommendations or when standard biomarker evaluation yields no targeted therapeutic option
- When a broad genomic profile identifies treatment options in clinical trials including immunotherapies and targeted therapies for patient enrollment
- When a cancer lacks an effective standard-of-care therapy at the time of diagnosis or when a tumor is poorly differentiated and of uncertain origin
- When relapse or disease progression has occurred prior therapies

---

OmniSeq INSIGHT delivers the distinct advantage of leveraging three NGS technologies, leading to the highest quality results:

- DNA sequencing to detect SNVs, indels, CNAs, TMB and MSI
- RNA sequencing by hybrid-capture to detect known and unknown fusion partners
- RNA gene expression profiling provides novel, differentiating insights into the tumor microenvironment



Identifies both known and unknown fusion partners



This approach fails to identify unknown fusion partners

*MSI - microsatellite instability; TMB - tumor mutational burden; SNVs - single nucleotide variants; indels - insertions/deletions; CNAs - copy number alterations; HRR - homologous recombination repair; HRD - homologous recombination deficiency; PARP - poly-ADP ribose polymerase.

Sample requirements (include pathology report)
Formalin fixed paraffin embedded (FFPE) tissue • Resection specimen • Needle core biopsies • Cell blocks from fine needle aspirates (FNAs) **Do not submit decalcified specimens, cytology smears or samples from hematologic malignancies**
FFPE block (preferred) or 20 unbaked, positively charged, unstained slides cut at 5 µm plus one H&E

Proven expertise in FFPE sample processing

A proprietary pre-analytical FFPE extraction process maximizes our ability to yield DNA and RNA sequencing data from limited specimen.

OmniSeq® high laboratory quality standards

- NYS CLEP approved
- ISO 13485 (2016) certified
- CLIA and CAP accredited

Powering better decisions

Result reporting

Turnaround time of 12-14 business days

Genetic Counselling

To schedule a complimentary expert consultation with a Dynacare Genetic Counsellor, call 888.988.1888.

Contact us

888.988.1888

Visit us

dynacare.ca

References

1. OmniSeq Bioinformatics Knowledgebase - data curation January 2021.

For more information about OmniSeq INSIGHT, call 888.988.1888
or e-mail genetics@dynacare.ca

Dynacare®

Genetics and Specialty Services

onc-2077-v1-0521 | L26428-0521-1